Kura Oncology, Inc. (NASDAQ: KURA) had its price target lowered by analysts at Scotiabank from $18.00 to $10.00. They now have a "sector perform" rating on the stock.
Kura Oncology Announces Senior Executive Promotions [Yahoo! Finance]
Kura Oncology Announces Senior Executive Promotions
Kura Oncology, Inc. (NASDAQ: KURA) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Kura Oncology and Kyowa Kirin Report Positive Combination Data for Ziftomenib at American Society of Hematology Annual Meeting [Yahoo! Finance]